[Interest of mycophenolate mofetil in children with membranous lupus nephritis].
The management of lupus nephritis remains a clinical problem in children as in adults. Corticosteroids, cyclophosphamide and azathioprine have been used with satisfactory response, but the most important problems are their potential toxicities. Therefore, we evaluate the use of mycophenolate mofetil (MMF) as a new agent for treatment of lupus nephritis in children. Five children with biopsy-proven proliferative glomerulonephritis with active lesions received MMF, combined with corticosteroids during the induction phase and alone during the maintenance phase. We retrospectively studied the efficacy and safety of this therapeutic regimen. All patients had proteinuria and renal failure. Four patients from five presented nephrotic syndrome. During the induction phase, three patients achieved complete remission of their nephrotic syndrome with normalization of renal function. One patient achieved partial remission and kept moderate renal failure. One patient died at 50 days by severe sepsis secondary to leucopenia. During the maintenance phase, three patients had complete remission. One patient was kept proteinuria with a creatinine clearance of 55 mL/min/1,73 m². The growth of these patients is not affected. In childhood lupus proliferative glomerulonephritis, MMF was well tolerated, and most of the patients achieved remission and improvement of their renal functions.